[Penile necrosis, a specific complication of prostatic artery embolization].
Nécrose pénienne, une complication spécifique de l’embolisation prostatique.
Benign prostatic hyperplasia
Dysfonction érectile
Dysuria
Dysurie
Embolisation de l’artère prostatique
Erectile dysfunction
Hypertrophie bénigne de prostate
Necrosis
Nécrose
Prostatic artery embolization
Journal
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
11
01
2023
revised:
06
04
2023
accepted:
12
04
2023
medline:
23
10
2023
pubmed:
9
5
2023
entrez:
8
5
2023
Statut:
ppublish
Résumé
Endoscopic surgery is the standard treatment for benign prostatic hyperplasia (BPH) refractory to pharmacological treatments. In order to reduce invasiveness and preserve sexual function, prostatic artery embolization (PAE) has been developed. However, the technical difficulties of carrying out this procedure and the results, which have yet to be confirmed, mean that it is not currently recommended. The seriousness of the complications generated should lead to a reflection on the benefit-risk balance. The objective is to report a case of penile ischemia after embolization of the prostatic arteries. A severe complication following prostatic artery embolization (PAE) is reported with its clinical and paraclinical evaluation before and after the procedure as well as the therapeutic management. Penile necrosis following prostatic artery embolization was reported in a 75-year-old patient despite an attempt of deobstruction. Lower urinary tract symptoms worsened postoperatively, associated with glans necrosis and refractory erectile dysfunction. The place of PAE in the therapeutic arsenal of BPH needs to be confirmed. This innovative technique exposes the patient to potentially severe risks such as penile ischemia, not encountered in conventional endoscopic surgical treatment. PAE should not be included in the therapeutic armamentarium for BPH outside of clinical trials.
Identifiants
pubmed: 37156687
pii: S1166-7087(23)00089-1
doi: 10.1016/j.purol.2023.04.003
pii:
doi:
Types de publication
Case Reports
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
407-411Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.